Hi ,
We hope this finds you well.
SynBioBeta is in Boston this week for the Ginkgo Ferment event. We are excited to help celebrate the bio-community’s progress over the past 18 months and look forward to understanding how together we can make biology easier to engineer.
Closer to home, we invite you all to consider attending two of SynBioBeta’s events:
Important to note: we have a limited number of discounted rooms available at the Oakland Marriott City Center for our January event, so reserve your room now for maximum savings.
We look forward to seeing you all soon!
Larry
Larry
|
 |
Larry Upton
Editor in Chief
larry.upton@synbiobeta.com
|
|
|
Spotlight on Phytolon |
|
|
 |
What makes red velvet cake so distinctive, alternative meats look appealing, and candies pop off the shelf? The color, of course! Food colorings used to be made from petrochemicals, but, to be more sustainable, the food industry has changed to natural dyes from plants. The problem? Crops grown for food coloring take away valuable farmland needed to feed our growing population. These colors are also less bright and shelf stable. Meet Phytolon, an Israeli company producing vibrant, long-lasting, and sustainable food colors by fermenting engineered baker’s yeast! Learn more about Phytolon’s colors on their website and Twitter.
|
|
|
Spotlight on Checkerspot |
 |
When Charles Dimmler, co-founder and CEO of Checkerspot, was in college as a pre-med student majoring in history, he fell in love with science. Instead of pursuing medicine, he chose to be part of the intersection between business and biotechnology to solve global challenges like making better and greener materials. Today, Checkerspot is helping the world build a post-petroleum future with innovative materials, such as skis made with more sustainable materials derived from microalgae. Check out their work here as Checkerspot's WING Platform takes off!
|
|
|
|
Spotlight on Araceli Bio |
 |
Drug discovery is a probability game—what compounds have the highest likelihood of safely and effectively treating a disease? Current tools for discovering promising drug compounds are labor-intensive, expensive, and slow. But Araceli Biosciences is working to change that. Through a combination of advanced hardware and AI software, the company’s high-content analysis platform—essentially, a very fast, automated scanner—images cells in very high detail and analyzes a drug compound’s effects. Traditionally, this process can take weeks. Araceli’s process happens in hours. Learn more about how Araceli is helping discover much-needed therapies faster!
|
|
|
|
|
|
|
 |
Synbio upgrade enables bacterium to carry out unnatural reaction |
To bridge the gap between the natural and the unnatural worlds, scientists based at the University of California (UC), Berkeley, and Lawrence Berkeley National Laboratory have engineered a bacterium that is capable of unnatural biosynthesis.
|
Keep Reading »
|
|
 |
Sana Biotechnology inks $50M deal for precise gene editing system from Beam Therapeutics |
"Our long-term aspirations are to be able to control or modify any gene in the body, to replace any cell that is damaged or missing, and to markedly improve access to cellular and gene-based medicines," stated the company.
|
Keep Reading »
|
|
|
 |
DNA Script raises $165M to accelerate commercialization of enzymatic DNA printing platform |
The SYNTAX Platform provides in-house DNA printing – without using toxic organic chemicals or extended delivery wait times from third-party DNA service providers – for labs of all sizes.
|
Keep Reading »
|
|
 |
Turning planet-warming methane into food-growing biostimulants |
Indian biotech company String Bio has announced a viable new technology that can turn the greenhouse gas methane into a valuable crop input.
|
Keep Reading »
|
|
|
 |
Chemicals & Materials Digital Conference
|
November 17th, 2021
|
Get ahead of the game and prepare for Chemicals and Materials to save yourself time and get the most out of your event. The Swapcard app makes it easy to connect with the right people in advance and register for the sessions you do not want to miss! Our live Q&As and networking opportunities are only live once and these could be your moments to connect with a community member.
|
Learn more »
|
|
|
|
|
Mammoth Biosciences inks $691 million deal with Vertex for CRISPR gene-editing therapies
|
Keep Reading »
|
|
|
New tool offers ways to improve CRISPR gene-editing method
|
Keep Reading »
|
|
|
Selecta Biosciences and Ginkgo Bioworks to advance treatments for orphan and rare diseases
|
Keep Reading »
|
|
|
Another milestone: LogicBio successfully edits genes in children
|
Keep Reading »
|
|
|
Join our event: A luncheon and panel discussion to connect, support, and elevate women in synthetic biology in Scotland!
|
Keep Reading »
|
|
|
BioBuilder is celebrating its 10th birthday by hosting a livestream from their new BioBuilder Learning Lab on Friday Nov. 5th
|
Keep Reading »
|
|
|
Synthetic biology innovator opens new campus to speed up drug discovery
|
Keep Reading »
|
|
|
Revisiting and realizing the promises of synthetic biology
|
Keep Reading »
|
|
|
Berkeley Lights announces GSK acquires third Beacon® optofluidic system to expand antibody therapeutics development
|
Keep Reading »
|
|
|
|
|
